{"id":147714,"date":"2026-11-10T20:38:23","date_gmt":"2026-11-10T11:38:23","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4554-20261110-01_wp_financial_summary\/"},"modified":"2026-11-10T20:38:23","modified_gmt":"2026-11-10T11:38:23","slug":"4554-20261110-01_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/","title":{"rendered":"Fuji Pharma Co., Ltd. Financial Summary for the Fiscal Year Ended September 2026 [Japanese GAAP] (Consolidated) [Latest]"},"content":{"rendered":"<p>Consolidated revenue for the fiscal year ended September 2026 increased to the 62,386 million yen range (62,386 million yen, +20.7% YoY). Operating income was 6,355 million yen (+27.4%), ordinary income was 6,176 million yen (+38.5%), but net income attributable to owners of parent decreased to 2,831 million yen (-5.6%). Forecasts for the next fiscal year are revenue of 69,190 million yen (+10.9%), operating income of 7,420 million yen (+16.8%), and net income of 4,880 million yen (+72.4%). Dividends are planned at 23 yen interim and 29 yen year-end, totaling 52 yen, continuing a progressive dividend policy targeting a payout ratio of 30% or more.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4554","jir_company_name":"Fuji Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4554-20261110-01.pdf","jir_short_summary":"Consolidated revenue for the fiscal year ended September 2026 increased to the 62,386 million yen range (62,386 million yen, +20.7% YoY). Operating income was 6,355 million yen (+27.4%), ordinary income was 6,176 million yen (+38.5%), but net income attributable to owners of parent decreased to 2,831 million yen (-5.6%). Forecasts for the next fiscal year are revenue of 69,190 million yen (+10.9%), operating income of 7,420 million yen (+16.8%), and net income of 4,880 million yen (+72.4%). Dividends are planned at 23 yen interim and 29 yen year-end, totaling 52 yen, continuing a progressive dividend policy targeting a payout ratio of 30% or more.","jir_summary":"### Performance Overview\nThe Fuji Pharma Co., Ltd. Group is promoting its medium-term management plan under the \"Long-term Vision 2035,\" positioning four areas\u2014women's healthcare, biosimilars, global CMO, and one other growth area\u2014as growth drivers. Consolidated revenue for the fiscal year ended September 2026 was 62,386 million yen, a substantial increase year-on-year. Operating income was 6,355 million yen and ordinary income was 6,176 million yen, both marking significant increases. However, due to impairment losses on investment securities and impairments of long-term prepayments, net income attributable to owners of parent declined to 2,831 million yen compared with the prior year. For the next fiscal year, the Company forecasts revenue of 69,190 million yen, operating income of 7,420 million yen, and net income of 4,880 million yen, expecting profit growth.\n\n### Dividends, Financial Position and Outlook\nThe dividend policy remains progressive; for this fiscal year, an interim dividend of 23 yen and a year-end dividend of 29 yen are planned, totaling 52 yen. While the medium-term plan anticipates increased R&D spending, the Company intends to secure profits through expense management. The financial position shows total assets of 98,287 million yen, net assets of 52,451 million yen, and an equity ratio of 53.4%. Cash flows are: operating CF 6,174 million yen, investing CF -3,630 million yen, financing CF -429 million yen, and cash and cash equivalents of 9,496 million yen.","jir_financial_highlights":"Revenue: 62,386 million yen (YoY +20.7%)\nOperating Income: 6,355 million yen (YoY +27.4%)\nOrdinary Income: 6,176 million yen (YoY +38.5%)\nNet Income Attributable to Owners of Parent: 2,831 million yen (YoY -5.6%)\nNet Assets per Share: 2,007.92 yen (YoY +)","jir_category":"","jir_hashtags":"#FujiPharma, #Earnings, #MidTermManagementPlan, #Biosimilars, #WomensHealthcare, #GlobalCMO","jir_key_figures":"Revenue: 62,386 million yen (YoY +20.7%)\nOperating Income: 6,355 million yen (YoY +27.4%)\nNet Income Attributable to Owners of Parent: 2,831 million yen (YoY -5.6%)","jir_meta_title":"Fuji Pharma Co., Ltd. FY2026 Financial Summary | Revenue 62,386 million yen, Operating Income 6,355 million yen","jir_meta_description":"Financial summary for Fuji Pharma Co., Ltd. for the fiscal year ended September 2026. Revenue 62,386 million yen, operating income 6,355 million yen, net income 2,831 million yen. Next fiscal year revenue forecast: 69,190 million yen. Dividends totaled 52 yen. Key points on the medium-term growth strategy and financial condition.","jir_og_title":"Fuji Pharma Co., Ltd. Financial Results for FY2026","jir_og_description":"Key points of Fuji Pharma Co., Ltd.'s financial results for the fiscal year ended September 2026: revenue, operating income, net income trends, next fiscal year outlook and dividend policy summarized.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[51677,62386]}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[4990,6355]}]}\"}, {\"jir_chart_id\": \"ordinary_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Ordinary Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Ordinary Income\\\",\\\"data\\\":[4459,6176]}]}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[3000,2831]}]}\"}, {\"jir_chart_id\": \"net_asset_per_share\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Assets per Share\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Assets per Share\\\",\\\"data\\\":[1907.82,2007.92]}]}\"}]","ir_related_company":17504,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-147714","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fuji Pharma Co., Ltd. Financial Summary for the Fiscal Year Ended September 2026 [Japanese GAAP] (Consolidated) [Latest] - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/\",\"name\":\"Fuji Pharma Co., Ltd. Financial Summary for the Fiscal Year Ended September 2026 [Japanese GAAP] (Consolidated) [Latest] - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-10T11:38:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fuji Pharma Co., Ltd. Financial Summary for the Fiscal Year Ended September 2026 [Japanese GAAP] (Consolidated) [Latest]\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fuji Pharma Co., Ltd. Financial Summary for the Fiscal Year Ended September 2026 [Japanese GAAP] (Consolidated) [Latest] - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/","name":"Fuji Pharma Co., Ltd. Financial Summary for the Fiscal Year Ended September 2026 [Japanese GAAP] (Consolidated) [Latest] - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-10T11:38:23+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-01_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Fuji Pharma Co., Ltd. Financial Summary for the Fiscal Year Ended September 2026 [Japanese GAAP] (Consolidated) [Latest]"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"17504","title":"FUJI PHARMA CO LTD","ticker":"4554"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/147714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=147714"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/147714\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=147714"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=147714"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=147714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}